RT @Joshilabyale: “In other words, DCs are the ‘best supporting actors’ of anti-tumor immunity.”. I guess that makes the T cell Marlon Bran….

Happy to share a link to our recent review of dendritic cells in cancer, written together with the great @MempelThorsten @csgarrix and @DiPilatoMauro. Here is a link giving full access to the paper:

What do you want to know?.

RT @ACIR_org: Bill and Wirapati et al. @RubenBill5 asked if common TME cellular processes control complex and variable patient outcomes. ht….

RT @CD_AACR: Read Cancer Discovery's #ResearchWatch:.CXCL9:SPP1 Macrophage Polarity Is Linked to Clinical Outcome in Cancer, summarizing th….

9/ 😀📚 If you're hungry for more insights into how patient variation may help us unravel the complexities of cancer, don't miss the full publication here:

8/ 🙌 Of course, it takes a village to conduct a study like this, so a hearty thank you, and bravo, to all the clinicians, nurses, researchers, bioinformaticians, technicians and many more, who made this study possible.

7/ 🎯 In essence, patient variation isn't just a challenge, it's an opportunity. By harnessing the differences between individuals, the study revealed that a simple yet powerful variable, CS macrophage polarity, is linked to human cancer outcomes.

6/ 🌐 But wait, there's more! These findings weren't limited to head and neck squamous cell carcinoma. The implications extended to other cancer types, highlighting the potentially universal importance of CS macrophage polarity.

5/ 🤝 What's even more intriguing is that CS macrophage polarity acted as a linchpin in a well-coordinated network involving various tumor-associated cell types. This intricate web influenced tumor progression, potentially revealing new targets for therapies.

4/ 🧬 The CXCL9:SPP1 ratio proved to be a powerful prognostic indicator. Tumors with different macrophage polarities had very different clinical outcomes and responses to immunotherapy. 📈📉.

3/ ✳️ Macrophages, immune cells with multiple roles, emerged as key components in this study. Instead of using conventional M1 and M2 markers, we defined macrophage polarity using CXCL9 and SPP1 (CS) gene expression. This approach provided remarkable insights!.

2/ 🧪 We took on the challenge of deciphering TMEs by studying 52 head and neck squamous cell carcinomas and discovered that tumor-to-tumor variation can reveal intratumoral cellular programs and disease outcomes. 📊.

1/ 🌍 Tumor microenvironments (TMEs) are like unique ecosystems within each cancer patient. They control disease progression, but their complexity makes them difficult to study. Here, we explored whether patient-to-patient variations can reveal insightful information about TMEs.

📢 Research Alert! 🧬🔬 🩺 We are super excited that our latest study, led by the great @RubenBill5 & Asa Wirapati, is out: We set out to shed some light on the tumor microenvironment and its impact on cancer progression. 🧵.

Congratulations Johanna!.

RT @janduslab: 📣 📣 Do you leave close to Geneva and want to participate in an out-of-the box Virtual Reality-based neuroimmunology project?….

What a fantastic study!.

RT @Harvard: The findings suggest that researchers may be able to manipulate neutrophils to make cancer therapies more effective https://t.….

Thank you also to Ann Ager for discussing both papers here:

👉 We also want to advertize a related paper by the team of @merghout and @wolchokj, published in the same issue, which reveals additional insights about the role of neutrophils in mediating effective cancer immunotherapy. 👉